MYOS RENS Technology Inc. (NASDAQ:MYOS) CEO Joseph Mannello purchased 25,000 shares of the firm’s stock in a transaction dated Thursday, November 16th. The stock was acquired at an average price of $1.31 per share, with a total value of $32,750.00. Following the purchase, the chief executive officer now directly owns 203,560 shares of the company’s stock, valued at $266,663.60. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
Joseph Mannello also recently made the following trade(s):
- On Tuesday, November 14th, Joseph Mannello acquired 11,750 shares of MYOS RENS Technology stock. The stock was purchased at an average cost of $1.27 per share, with a total value of $14,922.50.
Shares of MYOS RENS Technology Inc. (NASDAQ:MYOS) opened at $1.41 on Tuesday. MYOS RENS Technology Inc. has a 52-week low of $1.02 and a 52-week high of $6.98.
MYOS RENS Technology (NASDAQ:MYOS) last posted its earnings results on Tuesday, November 14th. The company reported ($0.13) EPS for the quarter. MYOS RENS Technology had a negative return on equity of 71.14% and a negative net margin of 941.41%. The firm had revenue of $0.16 million during the quarter.
Separately, ValuEngine raised MYOS RENS Technology from a “strong sell” rating to a “sell” rating in a research note on Wednesday, September 6th.
COPYRIGHT VIOLATION WARNING: This piece of content was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another domain, it was stolen and republished in violation of U.S. & international trademark and copyright legislation. The original version of this piece of content can be accessed at https://www.dispatchtribunal.com/2017/12/05/myos-rens-technology-inc-myos-ceo-acquires-32750-00-in-stock.html.
MYOS RENS Technology Company Profile
MYOS RENS Technology Inc (MYOS), formerly MYOS Corporation, is an early-stage bionutrition and biotherapeutics company. The Company is focused on the discovery, development and commercialization of products that improve muscle health and function essential for the management of sarcopenia, cachexia and degenerative muscle diseases, and as an adjunct to the treatment of obesity.
Receive News & Ratings for MYOS RENS Technology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MYOS RENS Technology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.